{"analyses":[{"ciLowerLimit":"-23.1","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"15.9","groupDescription":"Difference in response rate Arm2 - Arm1","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Unconditional exact method","paramValue":"-4"},{"ciLowerLimit":"2.5","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"40.7","groupDescription":"Difference in response rate Arm3 - Arm1","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Unconditional exact method","paramValue":"22"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"10"}]}],"title":"CR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"31"}]}],"title":"PR"}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"54"},{"groupId":"OG002","value":"54"}],"units":"Participants"}],"description":"Best overall response is defined as complete response (CR: the disappearance of all target lesions. Any pathological lymph nodes must be \\<10 millimeters \\[mm\\] in the short axis.) or partial reponse (PR: at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters \\[e.g., percent change from Baseline\\]). Participants with unknown or missing responses were considered as non-responders. To be assigned a status of PR or CR, a confirmatory disease assessment should have been performed no less than 28 days after the criteria for response were first met. Response was evaluated by an investigator as per Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.","groups":[{"description":"Participants received dabrafenib 150 mg gelatin capsules BID.","id":"OG000","title":"Part C: Dabrafenib 150 mg"},{"description":"Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD.","id":"OG001","title":"Part C: Dabrafenib 150 mg + Trametinib 1 mg"},{"description":"Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD.","id":"OG002","title":"Part C: Dabrafenib 150 mg + Trametinib 2 mg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Intent-to-Treat (ITT) Population: all randomized participants regardless of whether or not treatment was administered","reportingStatus":"POSTED","timeFrame":"From the first dose of study medication to the first documented evidence of a confirmed complete response or partial response (up to approximately 7 years)","title":"Part C (Randomized): Number of Participants With BRAF Mutant Metastatic Melanoma With Best Overall Response as Assessed by the Investigator","type":"PRIMARY","unitOfMeasure":"Participants"}